ABSTRACT
Background: Glucagon-like peptide-1 receptor-agonists (GLP-1ra), such as semaglutide, have emerged as promising treatments, demonstrating sustained weight reduction and metabolic benefits. This study aims to assess the impact of oral and subcutaneous semaglutide on body composition and metabolic parameters in patients with T2DM and obesity. Methods: A 24-week quasi-experimental retrospective study including adults with T2DM and obesity (BMI ≥ 30 kg/m²) who were treated with either daily-oral or weekly-subcutaneous semaglutide. Body composition was measured using bioelectrical impedance analysis, evaluating fat mass, fat-free mass, total body water, skeletal muscle mass, and whole-body phase angle. Analytical parameters included lipid profile and glycaemic control. Statistical analyses were performed using SPSS v.26. Results: Participants (n=88) experienced significant weight loss after treatment with semaglutide (9.5% in subcutaneous, 9.4% in oral, P<0.001). Weight reduction primarily resulted from fat mass reduction without substantial lean mass compromise. Visceral fat area decreased, whiles phase-angle remained stable. Improvements in lipid profiles and glycaemic control were observed, with a decrease in both HbA1c and insulin requirements. Multivariate analysis demonstrated comparable impacts of oral and subcutaneous semaglutide on body composition. Conclusion: Semaglutide, administered orally or subcutaneously, demonstrated positive effects on body composition, metabolic and glycaemic control in patients with T2DM and obesity. This real-world study highlights the potential of bioelectrical impedance analysis in assessing antidiabetic drugs' impact on body composition, providing valuable insights for future research and clinical applications.
Subject(s)
Body Composition , Diabetes Mellitus, Type 2 , Glucagon-Like Peptides , Hypoglycemic Agents , Obesity , Humans , Glucagon-Like Peptides/therapeutic use , Glucagon-Like Peptides/administration & dosage , Diabetes Mellitus, Type 2/drug therapy , Body Composition/drug effects , Male , Female , Middle Aged , Retrospective Studies , Obesity/drug therapy , Adult , Hypoglycemic Agents/therapeutic use , Aged , Weight Loss/drug effects , Blood Glucose/drug effects , Blood Glucose/metabolismABSTRACT
Objective: To assess the clinical impact of flash glucose monitoring (FGM) systems on fear of hypoglycemia (FoH) and quality of life in adults with type 1 diabetes mellitus (T1DM). Methods: Prospective quasi-experimental study with a 12-month follow-up. People with T1DM (18-80 years old) and self-monitoring by blood capillary glycemia controls were included. The FH15 questionnaire, a survey validated in Spanish in a comparable study population, was used to diagnose FoH with a cutoff point of 28 points. Results: A total of 181 participants were included, with a FoH prevalence of 69% (n = 123). A mean reduction in FH15 score of -4 points (95% confidence interval [-5.5 to -3]; P < 0.001) was observed, along with an improvement in quality of life (EsDQOL-test (Diabetes Quality of Life, Spanish version), -7 points [-10; -4], P < 0.001) and satisfaction with treatment (Diabetes Treatment Satisfaction questionnaire, self-reported version [DTSQ-s] test, +4.5 points [4; 5.5], P < 0.001). At the end of the follow-up, 64.2% of the participants saw an improved FoH intensity, compared to 35.8% who scored the same or higher. This improvement in FoH status was associated with a higher time-in-range at the end of the follow-up (P = 0.003), as well as a lower time spent in hyperglycemia (P = 0.005). In addition, it was linked to participants with a high baseline FoH levels (P < 0.001) and those who were university degree holders (P = 0.07). Conclusions: FGM is associated with an overall reduction of FoH in adults with T1DM and with an increase in their quality of life. Nevertheless, a significant percentage of patients may experience an increase of this phenomenon leading to clinical repercussions and a profound impact on quality of life.
Subject(s)
Blood Glucose Self-Monitoring , Diabetes Mellitus, Type 1 , Fear , Hypoglycemia , Quality of Life , Humans , Diabetes Mellitus, Type 1/psychology , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/drug therapy , Adult , Blood Glucose Self-Monitoring/psychology , Male , Female , Fear/psychology , Middle Aged , Hypoglycemia/psychology , Hypoglycemia/blood , Hypoglycemia/chemically induced , Aged , Prospective Studies , Young Adult , Adolescent , Blood Glucose/analysis , Aged, 80 and over , Surveys and QuestionnairesABSTRACT
BACKGROUND: The immune mechanism involved in the reaction to hydrochlorothiazide, which is widely used to control hypertension, is unknown. The short latency period between the take of the drug and the onset of symptoms suggests immediate hypersensitivity. CASE REPORT: 63-year-old woman with arterial hypertension who, on three occasions, experienced nausea, vomiting, general malaise, shivering, arthralgias, dysthermic sensation, back pain of mechanical characteristics and mild non-productive cough, as well as fever and chest tightness with increased dyspnea and desaturation of up to 88 %, after taking hydrochlorothiazide. CONCLUSIONS: Clinical presentation in the patient was similar to a septic shock, which is a rare allergic reaction. The diagnosis has to be clinical. This type of reaction might be due to type III hypersensitivity owing to the formation of immune complexes. Avoiding of the culprit drug is key to a good evolution.
Antecedentes: Se desconoce el mecanismo inmunológico implicado en la reacción a la hidroclorotiazida, de amplio uso para el control de la hipertensión arterial. El corto periodo de latencia entre la toma del fármaco y la aparición de síntomas sugiere hipersensibilidad inmediata. Reporte de caso: Mujer de 63 años con hipertensión arterial quien en tres ocasiones presentó náuseas, vómitos, malestar general, tiritona, artralgias, sensación distérmica, dolor lumbar de características mecánicas y tos escasa no productiva, así como fiebre y opresión torácica con incremento de la disnea y desaturación hasta de 88 %, tras la toma de hidroclorotiazida. Conclusiones: La presentación clínica en la paciente fue similar a choque séptico, reacción alérgica rara cuyo diagnóstico es clínico Este tipo de reacción podría deberse a hipersensibilidad tipo III debido a la formación de inmunocomplejos. Evitar el fármaco implicado es clave para la buena evolución.
Subject(s)
Antihypertensive Agents/adverse effects , Hydrochlorothiazide/adverse effects , Hypertension/drug therapy , Female , Humans , Middle Aged , Severity of Illness IndexABSTRACT
BACKGROUND: Eosinophilic esophagitis (EE) is an emerging worldwide disease that mimics gastroesophageal reflux disease. OBJECTIVE: Early studies have suggested that esophageal eosinophilia occurs in association with T(H)2 allergic responses, yet the local and systemic expression of relevant cytokines has not been well characterized. METHODS: A human inflammatory cytokine and receptor PCR array containing 84 genes followed by PCR validation and multiplex arrays were used to quantify cytokine mRNA in esophageal biopsies and blood samples. RESULTS: Esophageal transcripts of numerous chemokines (eg, chemokine [C-C motif] ligand [CCL] 1, CCL1, CCL23, CCL26 [eotaxin-3], chemokine [C-X-C motif] ligand [CXCL] 1, and CXCL2), cytokines (eg, IL13 and ATP-binding cassette, subfamily F, member 1), and cytokine receptors (eg, IL5 receptor, alpha) were induced at least 4-fold in individuals with EE. Analysis of esophageal biopsies (n = 288) revealed that eotaxin-3 mRNA level alone had 89% sensitivity for distinguishing individuals with and without EE. The presence of allergy was associated with significantly increased esophageal expression of IL4 and IL5 mRNA in patients with active EE. We identified 8 cytokines (IL-4, IL-13, IL-5, IL-6, IL-12p70, CD40 ligand, IL-1α, and IL-17) whose blood levels retrospectively distinguished 12 patients without EE from 13 patients with EE with 100% specificity and 100% sensitivity. When applied to a blind, prospectively recruited group of 36 patients, the cytokine panel scoring system had a 79% positive predictive value, 68% negative predictive value, 61% sensitivity, and 83% specificity for identifying EE. CONCLUSION: Evidence is presented that IL13 and IL5 associate with eosinophil and eotaxin-3 levels, indicating the key role of adaptive T(H)2 immunity in regulating eotaxin-3-driven esophageal eosinophilia in the absence of a consistent systemic change in cytokines.
Subject(s)
Cytokines/biosynthesis , Eosinophilic Esophagitis/immunology , Eosinophilic Esophagitis/metabolism , Cytokines/blood , Eosinophilic Esophagitis/diagnosis , Esophagus/immunology , Esophagus/metabolism , Humans , Oligonucleotide Array Sequence Analysis , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity , Th2 CellsABSTRACT
BACKGROUND: Hypersensitivity reactions to metronidazole are infrequently described. However, we believe that such reactions are increasing due to growing use of the drug for the treatment of amebiasis and anaerobe infections combined with other antibiotics. The present study assesses the need for oral provocation in patients with probable hypersensitivity reactions to metronidazole. METHODS: We performed cutaneous prick tests with spiramycin and metronidazole as well as epicutaneous tests with metronidazole at different concentrations in four patients with cutaneous reactions to Rhodogil (metronidazole plus spiramicyn). Controlled oral challenges were then carried out with placebo using erythromycin, spiramycin and metronidazole except in the last patient due to a positive prick test. RESULTS: Only one patient showed a positive metronidazole prick test. The epicutaneous tests were negative. All patients tolerated erythromycin and spiramycin up to therapeutic doses. Oral provocation with metronidazole proved positive, the first patient presenting a delayed exanthema and the other two early erythema and itching. CONCLUSIONS: We present four cases of cutaneous exanthemas caused by metronidazole (two early and two delayed) and probably mediated by an immune mechanism which we have only been able to demonstrate in one case. Taking into account the low sensitivity of the cutaneous tests (prick tests and epicutaneous tests), oral provocation must be considered the "gold standard" for establishing the diagnosis in many cases of hypersensitivity reactions to metronidazole.
Subject(s)
Drug Hypersensitivity/etiology , Metronidazole/adverse effects , Adult , Angioedema/etiology , Drug Combinations , Drug Hypersensitivity/diagnosis , Exanthema/etiology , Female , Humans , Male , Metronidazole/administration & dosage , Metronidazole/immunology , Middle Aged , Predictive Value of Tests , Pruritus/etiology , Skin Tests , Spiramycin/administration & dosageABSTRACT
Background: Hypersensitivity reactions to metronidazole are infrequently described. However, we believe that such reactions are increasing due to growing use of the drug for the treatment of amebiasis and anaerobe infections combined with other antibiotics. The present study assesses the need for oral provocation in patients with probable hypersensitivity reactions to metronidazole. Methods: We performed cutaneous prick tests with spiramycin and metronidazole as well as epicutaneous tests with metronidazole at different concentrations in four patients with cutaneous reactions to Rhodogil® (metronidazole plus spiramicyn). Controlled oral challenges were then carried out with placebo using erythromycin, spiramycin and metronidazole except in the last patient due to a positive prick test. Results: Only one patient showed a positive metronidazole prick test. The epicutaneous tests were negative. All patients tolerated erythromycin and spiramycin up to therapeutic doses. Oral provocation with metronidazole proved positive, the first patient presenting a delayed exanthema and the other two early erythema and itching. Conclusions: We present four cases of cutaneous exanthemas caused by metronidazole (two early and two delayed) and probably mediated by an immune mechanism which we have only been able to demonstrate in one case. Taking into account the low sensitivity of the cutaneous tests (prick tests and epicutaneous tests), oral provocation must be considered the "gold standard" for establishing the diagnosis in many cases of hypersensitivity reactions to metronidazole
Antecedentes: Las reacciones de hipersensibilidad por metronidazol descritas no son frecuentes. Sin embargo, creemos que están aumentando debido a su mayor uso para el tratamiento de amebiasis e infecciones por anaerobios combinado con otros antibióticos. Nuestro objetivo fue valorar la necesidad de la provocación oral en pacientes con probables reacciones de hipersensibilidad por metronidazol. Métodos: Se realizaron pruebas cutáneas en prick con espiramicina y metronidazol así como pruebas epicutáneas con éste último a distintas concentraciones en cuatro pacientes que consultaron por reacciones cutáneas con Rhodogil® (metronidazol más espiramicina. A continuación se llevaron a cabo provocaciones orales controladas con placebo con eritromicina, espiramicina y metronidazol. Resultados: El prick sólo fue positivo para metronidazol en uno de los casos. Las pruebas epicutáneas fueron negativas. Todos los pacientes toleraron la eritromicina y espiramicina hasta dosis terapeúticas. La provocación oral con metronidazol fue positiva (excepto en el último paciente por la positividad del prick), presentando el primer paciente un exantema tardío y los otros dos eritema y prurito de forma precoz. Conclusiones: Presentamos cuatro casos de exantemas cutáneos por metronidazol (dos precoces y dos tardíos) probablemente mediados por un mecanismo inmunológico que sólo hemos podido demostrar en uno de ellos. Teniendo en cuenta la baja sensibilidad de las pruebas cutáneas, tanto en prick como epicutáneas, la provocación oral debe considerarse como el gold standard necesario para llegar al diagnóstico de muchos casos de reacciones de hipersensibilidad por metronidazol
